Riverwater Partners, an investment management company, released its “Small Cap Strategy” Q1 2026 investor letter. A copy of the letter can be downloaded here. In Q1 2026, the Riverwater Small Cap Strategy outperformed the Russell 2000 Index. The quarter rewarded patience and discipline. The first quarter of 2026 saw a significant shift in market leadership and risk perceptions, due to geopolitical tensions in the Middle East and concerns over sustainable growth in the software and AI sectors. Additionally, private credit markets are under stress. In this environment, the firm is concentrating on identifying market dislocations caused by what it perceives as indiscriminate selling, particularly in AI-related areas. In addition, please check the Strategy’s top five holdings to know its best picks in 2026.
In its first-quarter 2026 investor letter, Riverwater Partners Small Cap Strategy highlighted stocks like AtriCure, Inc. (NASDAQ:ATRC). AtriCure, Inc. (NASDAQ:ATRC) is a medical device company focused on the development and manufacture of technologies for the surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporary pain management. On May 4, 2026, AtriCure, Inc. (NASDAQ:ATRC) closed at $28.78 per share. One-month return of AtriCure, Inc. (NASDAQ:ATRC) was 0.17%, and its shares lost 3.05% over the past 52 weeks. AtriCure, Inc. (NASDAQ:ATRC) has a market capitalization of $1.46 billion.
Riverwater Partners Small Cap Strategy stated the following regarding AtriCure, Inc. (NASDAQ:ATRC) in its Q1 2026 investor letter:
“AtriCure, Inc. (NASDAQ:ATRC) underperformed during the first quarter of 2026 despite delivering a strong earnings report and providing 2026 guidance that came in above street expectations, reflecting continued momentum across its core atrial fibrillation and appendage management businesses. The stock’s weakness was driven less by fundamentals and more by a shift in investor sentiment following Edwards Lifesciences’ announcement of a competing surgical left atrial appendage closure (LAAC) product, which will directly compete with AtriCure’s AtriClip franchise. This development created an overhang on the shares, as investors reassessed the durability of AtriCure’s market leadership in appendage management. However, Edwards’ product is not expected to be fully available until late in 2026 or 2027, while AtriCure’s AtriClip is already well established and widely adopted among cardiac surgeons, supported by strong clinical data and entrenched physician relationships. In our view, the sell-off reflects near-term competitive concerns rather than a deterioration in the company’s underlying growth trajectory, and AtriCure remains well positioned given its first-mover advantage and deep integration within surgical workflows.”
